ArticleCanada communicable disease report = Releve des maladies transmissibles au Canada2026
Tracking Canada's 2015 vaccine research and development priorities: Where are we a decade later?
Article in Canada communicable disease report = Releve des maladies transmissibles au Canada, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tracking Canada's 2015 vaccine research and development priorities: Where are we a decade later?Canada communicable disease report = Releve des maladies transmissibles au Canada · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In 2015, Public Health Agency of Canada (PHAC) identified a set of priorities for research and development (R&D) of new and improved human and animal vaccines. Thirty human pathogens were grouped by vaccine development timeline (short: 0-6 years; medium: 7-12 years; long: 13 years or longer) and ranked by R&D priority (high, medium, low). Objective: To characterize the vaccine development pathway for these 30 pathogens to inform a 2025 update to PHAC's vaccine R&D priorities. Methods: For each pathogen, we conducted a targeted search for vaccines authorized in Canada since 2015 using the Health Canada Drug Product Database and Canadian Immunization Guide and for candidates in clinical trials, in the registry, ClinicalTrials.gov (primary completion date of May 1, 2015 or later). Search results were downloaded and filtered by study status, phase and type. For select pathogens, we conducted additional searches in published (PubMed) and grey literature (other trial registries, industry press releases, and Web searches). Results: Seven pathogens had at least one newly authorized vaccine since 2015: three of 13 high-priority (influenza, n=4; Conclusion: Although some of the pathogens on the 2015 list now have authorized vaccines or candidates in late-stage clinical development, important gaps persist, which will inform PHAC's 2025 vaccine R&D update.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.